United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - alprostadil (unii: f5td010360) (alprostadil - unii:f5td010360) - alprostadil 500 ug in 1 ml - alprostadil injection usp is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. in infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment po2 values; that is, patients with low po2 values respond best, and patients with po2 values of 40 torr or more usually have little response. alprostadil injection usp should be administered only by trained personnel in facilities that provide pediatric intensive care. none.

Canada - English - Health Canada

advanced dosage forms inc. - alprostadil - solution - 500mcg - alprostadil 500mcg - miscellaneous vasodilatating agents

United States - English - NLM (National Library of Medicine)

endo pharmaceuticals inc. - alprostadil (unii: f5td010360) (alprostadil - unii:f5td010360) - alprostadil 10 ug in 1 ml - edex® is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology. edex® should not be used: - in men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia [see warnings]. - for the treatment of erectile dysfunction in men with fibrotic conditions of the penis, such as cavernosal fibrosis or peyronie’s disease [see precautions]   - in men with penile implants

United States - English - NLM (National Library of Medicine)

u.s. pharmaceuticals - alprostadil (unii: f5td010360) (alprostadil - unii:f5td010360) - alprostadil 10 ug in 0.5 ml - caverject impulse is indicated for the treatment of erectile dysfunction. caverject impulse is indicated as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction. caverject impulse should not be used: - in men who have a known hypersensitivity to the drug [see adverse reactions (6.1)] - in men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia [see warnings and precautions (5.1)] - for the treatment of erectile dysfunction in men with fibrotic conditions of the penis, such as anatomical deformation, angulation, cavernosal fibrosis, or peyronie's disease [see warnings and precautions (5.2)] - in men with penile implants. caverject impulse is not indicated for use in females. caverject impulse is not indicated for use in females. caverject impulse is not indicated for use in pediatric patients [see warnings and precautions (5.8)] . a total of 341 subjects included in clinical studies were 65 and older. no o

United States - English - NLM (National Library of Medicine)

pharmacia and upjohn company llc - alprostadil (unii: f5td010360) (alprostadil - unii:f5td010360) - alprostadil 500 ug in 1 ml - prostin vr pediatric sterile solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. in infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment po2 values; that is, patients with low po2 values respond best, and patients with po2 values of 40 torr or more usually have little response. prostin vr pediatric should be administered only by trained personnel in facilities that provide pediatric intensive care. none.

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - alprostadil (unii: f5td010360) (alprostadil - unii:f5td010360) - alprostadil 20.5 ug in 1 ml - caverject is indicated for the treatment of erectile dysfunction. caverject is indicated as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction. caverject is contraindicated: caverject is not indicated for use in females. caverject is not indicated for use in females. safety and effectiveness have not been established in pediatric patients [see warnings and precautions (5.8)] . a total of 341 subjects included in clinical studies were 65 and older. no overall differences in safety and effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between elderly and younger patients. caverject [kav-er-jeckt]® (alprostadil) for injection, for intracavernosal use your healthcare provider should show you how to prepare and inject caverject the right way before you inject it for the first time. do not try to inject yourself until you have been shown the right way to give your injections by your healthcare provider. information about how to safely inject caverject: supplies you will need to give your caverject injection (figure a) these items are needed for injection and are not supplied with caverject : figure a: supplies you will need for your injection. follow the instructions below to prepare and give your injection. figure b explains the parts of the needle and syringe that are referred to in the instructions. figure b: parts of the needle and syringe caverject comes in 20 mcg or 40 mcg strengths. make sure you have the right strength vial of caverject that your healthcare provider prescribed for you. prepare the syringe step 1 . wash your hands thoroughly and dry them with a clean towel. step 2 . assemble the needle and syringe as follows: figure c: remove the syringe figure d: open the needle wrapper step 3 . keeping hold of the needle assembly, remove the plastic syringe cap from the syringe tip (figure e). do not touch the syringe tip. figure e: remove the syringe cap step 4 . hold the needle assembly (still in the paper wrapper). firmly attach the needle to the syringe tip. turn it clockwise, like tightening a screw to lock it in place (figure f). figure f: attach the needle to the syringe mixing the powder and liquid to prepare the dose step 5 . remove the plastic cap from the vial of caverject and remove any cover from the diluent (figure g). figure g: remove the vial cap step 6 . wipe the rubber stoppers on the vials of caverject and diluent with 1 alcohol swab. throw away the alcohol swab. step 7 . carefully hold the syringe by the barrel and remove the needle cover (figure h). figure h: remove the needle cover step 8 . hold the syringe with the needle attached and push the needle through the center of the diluent vial's rubber stopper (figure i). be careful not to bend the needle. figure i: push the needle into the diluent vial figure j: remove the liquid from the vial step 9 . push the syringe plunger to the 1ml mark on the syringe. this will remove air and extra liquid back into vial. grasp the side of the syringe barrel (not the plunger) and pull the needle from the diluent vial in a straight line to avoid bending the needle (figure k). figure k: adjust the amount of liquid in the syringe step 10 . holding the syringe with the needle attached in a straight line with the vial of caverject, push the needle through the center of the rubber stopper of the vial of caverject. be careful not to bend the needle . figure l: push the needle into the caverject vial step 11 . without removing the needle or touching the needle or stopper, gently swirl (do not shake) the vial until all the powder is dissolved in the liquid. then turn the vial and needle/syringe upside down and gently swirl the vial to dissolve any powder in the neck of the vial. do not use the solution if it is cloudy, colored, or contains particles. step 12 . keeping the needle in the vial, firmly hold the vial and syringe upside down in one hand. figure m: remove the liquid from the vial step 13 . if there are air bubbles, gently tap the syringe barrel until the bubbles float to the top of the liquid (see error! hyperlink reference not valid. ). figure n: tap the syringe barrel to remove air bubbles step 14 . carefully replace the needle used to mix the liquid with a new 29 to 30 gauge one half inch needle for your injection. set the syringe down on a level surface. how to give the injection step 15 . the injection will go into the part of the penis shown as the shaded area in figure o. do not inject caverject into the white areas because there may be blood vessels in the white areas. (see error! hyperlink reference not valid. ). figure o: top view of the penis showing injection sites (shaded areas). figure p: cross-section of the penis step 16 . wipe the area for injection with an alcohol swab and let it dry. step 17 . do not throw away the swab; you will need to use it again after you give your injection. (see error! hyperlink reference not valid. ). step 18 . if your penis is not circumcised, pull the foreskin back. take hold of the tip of your penis with your thumb and forefinger; stretch it lengthwise along your thigh. step 19 . gently squeeze your penis between your thumb and finger so that the injection site bulges out. step 20 . remove the cover from the needle. position your penis firmly against your thigh to keep it from moving during the injection. step 21 . keeping a firm grip on your penis, take the syringe in your other hand, and push the needle straight into the selected injection site (see error! hyperlink reference not valid. ). figure q: insert the needle into the injection site step 22 . holding the syringe barrel between two fingers, move your thumb or finger to the top of the plunger and, with a steady motion, push down on the plunger so that the entire contents of the syringe is slowly injected (figure r). figure r: inject the contents of the syringe. step 23 . after completing the injection, carefully pull the needle out of your penis. press gently on the injection site with the alcohol swab for about 5 minutes or until bleeding stops. after your injection: dispose of your used caverject syringe and needles. how should i store caverject? caverject 20 mcg vial storage information caverject 40 mcg vial storage information keep caverject and all medicines out of the reach of children. this patient information and instructions for use has been approved by the u.s food and drug administration. lab-0009-8.0 revised march 2023

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - alprostadil - powder for solution for injection - alprostadil 20 mcg/vial - alprostadil - alprostadil - treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic or mixed etiology. useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - alprostadil - powder for solution for injection - alprostadil 10 mcg - alprostadil - alprostadil - for the treatment of erectile dysfunction in adult males, due to neurogenic, vasculogenic, psychogenic or mixed etiology. useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprostadil -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprostadil -